Clinical Trial Update: Expanded Access to Telisotuzumab Vedotin

View source ↗

Summary

AbbVie has opened Expanded Access for Telisotuzumab Vedotin to patients with non-small cell lung cancer. The program status is AVAILABLE.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Telisotuzumab Vedotin (Telisotuzumab Vedotin)

Snippet

Sponsor: AbbVie | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Status: AVAILABLE